These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30924091)

  • 81. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
    Pfeiffer P; Sorbye H; Qvortrup C; Karlberg M; Kersten C; Vistisen K; Lindh B; Bjerregaard JK; Glimelius B
    Clin Colorectal Cancer; 2015 Sep; 14(3):170-6. PubMed ID: 25956187
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    Schimanski CC; Staib F; Göhler T; Hebart H; Heike M; Neise M; Rudi J; Geer T; Dingeldein G; Lang C; Ehscheidt P; Flohr T; Josten KM; Karthaus M; Schmittel A; Wierecky J; Boller E; Indorf M; Wörns MA; Galle PR; Moehler M
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1023-1034. PubMed ID: 28197787
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
    Kratz JD; Uboha NV; Lubner SJ; Mulkerin DL; Clipson L; Yi Y; Yu M; Matkowskyj KA; LoConte NK; Deming DA
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1442-1450. PubMed ID: 30545991
    [No Abstract]   [Full Text] [Related]  

  • 84. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
    Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
    J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
    Antonetti P; Fargnoli MC; Porzio G; Salvatore L; Filippi R; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Dell'Aquila E; Lombardi P; Keränen SR; Depetris I; Giampieri R; Morelli C; De Tursi M; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Cortellini A; Pensieri MV; Ficorella C; Ferri C; Parisi A
    Support Care Cancer; 2022 Mar; 30(3):2455-2465. PubMed ID: 34779921
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
    Marks E; Rizvi SM; Sarwani N; Yang Z; El-Deiry WS
    Cancer Biol Ther; 2015; 16(3):377-82. PubMed ID: 25695537
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Liu T; Jiang S; Teng X; Zhong L; Liu M; Jin Y; Dong M
    Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):1-9. PubMed ID: 35950851
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab.
    Brugger W
    Tumori; 2010; 96(3):473-7. PubMed ID: 20845811
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
    Sahin S; Karatas F
    J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
    Rezkallah KNM; Ahmed A; Patel S; Kozma K
    BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30739089
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
    Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
    [No Abstract]   [Full Text] [Related]  

  • 92. Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Taieb J; Geissler M; Rivera F; Karthaus M; Wilson R; Loupakis F; Price T; Tracy M; Burdon P; Peeters M
    Clin Colorectal Cancer; 2019 Dec; 18(4):245-256.e5. PubMed ID: 31515083
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.
    Fiala O; Veskrnova V; Chloupkova R; Poprach A; Kiss I; Kopeckova K; Dusek L; Slavicek L; Kohoutek M; Finek J; Svoboda M; Petruzelka L; Boubliková L; Dvorak J; Melichar B; Buchler T
    Target Oncol; 2018 Dec; 13(6):735-743. PubMed ID: 30353488
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial.
    Piccirillo MC; Avallone A; Carlomagno C; Maiello E; Rosati G; Alabiso O; Nasti G; De Placido S; Latiano TP; Bilancia D; Ottaiano A; De Stefano A; Romano C; Silvestro L; Nappi A; Cassata A; Giordano P; Iaffaioli RV; Normanno N; Perrone F; Daniele B
    Clin Colorectal Cancer; 2020 Dec; 19(4):270-276. PubMed ID: 32631788
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
    Berger AK; Lücke S; Abel U; Haag GM; Grüllich C; Stange A; Dietrich M; Apostolidis L; Freitag A; Trierweiler C; von Gall C; Ose J; Giesel F; Weber TF; Lordick F; Haberkorn U; Jäger D
    Br J Cancer; 2018 Jul; 119(2):170-175. PubMed ID: 29961759
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis.
    Rossini D; Germani MM; Pagani F; Pellino A; Dell'Aquila E; Bensi M; Liscia N; Moretto R; Boccaccino A; Prisciandaro M; Manglaviti S; Schirripa M; Vivolo R; Scartozzi M; Santini D; Salvatore L; Pietrantonio F; Loupakis F; Falcone A; Cremolini C
    Clin Colorectal Cancer; 2020 Sep; 19(3):191-199.e6. PubMed ID: 32466976
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study.
    Lim AR; Kim JH; Hyun MH; Kim YH; Lee S
    Support Care Cancer; 2022 Oct; 30(10):8129-8137. PubMed ID: 35779133
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
    Annunziata MC; De Stefano A; Fabbrocini G; Leo S; Marchetti P; Romano MC; Romano I
    Clin Drug Investig; 2019 Sep; 39(9):825-834. PubMed ID: 31264159
    [TBL] [Abstract][Full Text] [Related]  

  • 99. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer.
    Cardone C; Blauensteiner B; Moreno-Viedma V; Martini G; Simeon V; Vitiello PP; Ciardiello D; Belli V; Matrone N; Troiani T; Morgillo F; Zito Marino F; Dentice M; Nappi A; Boccaccino A; Antoniotti C; Cremolini C; Pietrantonio F; Prager GW; Normanno N; Maiello E; Argiles G; Elez E; Signoriello G; Franco R; Falcone A; Tabernero J; Sibilia M; Ciardiello F; Martinelli E
    Eur J Cancer; 2020 Oct; 138():1-10. PubMed ID: 32818762
    [TBL] [Abstract][Full Text] [Related]  

  • 100. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
    Chiang TY; Hsu HC; Jane SW; Chen SC
    Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.